Compare BH & PCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BH | PCRX |
|---|---|---|
| Founded | 1934 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.0B |
| IPO Year | N/A | 2011 |
| Metric | BH | PCRX |
|---|---|---|
| Price | $420.02 | $23.59 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $32.86 |
| AVG Volume (30 Days) | 60.2K | ★ 965.3K |
| Earning Date | 11-07-2025 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 7.91 | 0.47 |
| Revenue | $386,507,000.00 | ★ $716,791,000.00 |
| Revenue This Year | N/A | $6.24 |
| Revenue Next Year | N/A | $9.53 |
| P/E Ratio | $628.45 | ★ $49.92 |
| Revenue Growth | ★ 6.87 | 3.14 |
| 52 Week Low | $195.05 | $19.81 |
| 52 Week High | $424.48 | $27.64 |
| Indicator | BH | PCRX |
|---|---|---|
| Relative Strength Index (RSI) | 78.10 | 40.40 |
| Support Level | $346.56 | $24.20 |
| Resistance Level | $364.95 | $26.48 |
| Average True Range (ATR) | 15.80 | 1.06 |
| MACD | 7.27 | -0.23 |
| Stochastic Oscillator | 100.00 | 29.39 |
Biglari Holdings Inc is a holding company that owns subsidiaries in a range of businesses. The company's reportable segments include Restaurant Operations, Insurance Operations, Oil and Gas Operations. Company's restaurant operations include Steak n Shake and Western Sizzlin. Its insurance operations include First Guard, Southern Pioneer, and Biglari Reinsurance. Oil and gas operations include Southern Oil and Abraxas Petroleum. The Company also reports segment information for Maxim. The majority of revenue is derived from the Maxim Segment.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.